GNE.3230R1C122 Docket No.:

June 29, 2005

Page 1 of 1

Please Direct All Correspondence to Customer Number 30,313

TRANSMITTAL LETTER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Goddard, et al. (as previously amended)

App. No

10/063,685

Filed

May 8, 2002

For

A NUCLEIC ACID OVEREXPRESSED IN

KIDNEY TUMOR AND

UNDEREXPRESSED IN LUNG TUMOR

Examiner

Jegatheesan Seharaseyon

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 29, 2005

(Date)

AnneMarie Kalser, Reg. No. 37,649

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- A Supplemental Information Disclosure Statement and PTO/SB/08 equivalent listing references (X) for consideration:
 - Listing and enclosing 15 references. (X)
- The Commissioner is hereby authorized to charge any additional fees which may be required, or (X) credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

AnneMarie Kaiser

Registration No. 37,649

Attornex of Record

Customer No. 30,313

(619) 235-8550

1794295 062805

JUL 0 1 2005 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Goddard, et al. (as previously amended)

App. No

10/063,685

Filed

May 8, 2002

For

A NUCLEIC ACID

OVEREXPRESSED IN KIDNEY TUMOR AND UNDEREXPRESSED

IN LUNG TUMOR

Examiner

Jegatheesan Seharaseyon

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class in an envelope addressed Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450, on

> June 29, 2005 (Date)

AnneMarie Kaiser/Reg. No. 37,6

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a Supplemental Information Disclosure Statement by Applicant (PTO/SB/08 equivalent), listing 15 foreign patent references and/or non-patent literature to be considered by the Examiner.

This Supplemental Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By:

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

1794292 062805

SUPPLEMENTAL INFORMATION **DISCLOSURE**

Filing Date May 8, 2002 First Named Inventor Goddard, et al. (as previously amended) **TEMENT BY APPLICANT** Art Unit (Multiple sheets used when necessary) Examiner Jegatheesan Seharaseyon SHEET 1 OF 1 Attorney Docket No. GNE.3230R1C122

Application No.

10/063,685

T.		NON PATENT LITERATURE DOCUMENTS	
- CO1	RAPE	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials	No.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. Blood, 87(12):5257-5268.	
	2	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. Molecular & Cellular Proteomics 1.4, 304-313.	
	3	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal, Vol. 15, No. 16,</i> pp. 4392-4401.	
	4	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C βII Is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research, Vol. 61</i> , pp.1375-1381.	
	5	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	6	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	7	HANCOCK, W. S. 2004. Do We Have Enough Biomarkers? Journal of Proteome Research, 3(4):685.	
	8	HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis, Vol. 19,</i> pp. 1862-1871.	
	9	HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. Journal of Proteome Research, Vol. 2, pp. 405-412.	
	10	JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> 15(5): pp. 469-483	
	11	KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous Leukemia Patients, <i>National Academy of Sciences of the United States of America, Vol. 83, No. 11</i> , pp. 4049-4052	
	12	OHARA, et al. 2001. Directional cDNA library construction assisted by the in vitro recombination reaction. <i>Nucleic Acids Research, Vol. 29, No e22</i> , pp.1-8.	
	13	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics, Vol.5:</i> pp. 411-421.	
	14	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.	
	15	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	

1794280 062805

Examiner Signature

Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.